News
VERU
0.9480
+0.18%
0.0017
Weekly Report: what happened at VERU last week (0715-0719)?
Weekly Report · 4d ago
Buy Rating Affirmed for Veru’s Enobosarm on Positive Trial Results and Market Opportunity
TipRanks · 07/17 16:03
VERU INC <VERU.O>: JEFFERIES CUTS TARGET PRICE TO $1 FROM $1.2
Reuters · 07/17 15:26
Weekly Report: what happened at VERU last week (0708-0712)?
Weekly Report · 07/15 11:17
Weekly Report: what happened at VERU last week (0701-0705)?
Weekly Report · 07/08 11:18
Weekly Report: what happened at VERU last week (0624-0628)?
Weekly Report · 07/01 11:19
VERU Stock Earnings: Veru Beats EPS, Misses Revenue for Q1 2024
Veru reported results for the first quarter of 2024. Veru reported earnings per share of -8 cents. The company reported revenue of $2.14 million. This was 58.83% worse than the analyst estimate of $5.20 million for the quarter.
Investorplace · 06/26 11:53
Weekly Report: what happened at VERU last week (0617-0621)?
Weekly Report · 06/24 11:27
Veru Announces Safety and Body Composition Data from Two Late-Breaker Presentations at the American Diabetes Association's 84th Scientific Sessions
Veru Inc. Announced data from two late-breaker presentations at the American Diabetes Association's 84th Scientific Sessions. Veru is a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for weight loss, oncology and viral induced respiratory distress syndrome.
Barchart · 06/24 07:30
Press Release: Veru Adjourns 2024 Annual Meeting of Shareholders to June 27, 2024
Dow Jones · 06/18 20:05
Veru Adjourns 2024 Annual Meeting of Shareholders to June 27, 2024
Veru Inc. Is a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle. The company's Annual Meeting of Shareholders was convened and adjourned without a required quorum due to lack of a quorum. Veru's annual meeting was scheduled for today.
Barchart · 06/18 15:05
Press Release: Veru Reminds Shareholders to Vote in Advance of Tomorrow's Deadline for 2024 Annual Meeting of Shareholders
Dow Jones · 06/17 20:45
Weekly Report: what happened at VERU last week (0610-0614)?
Weekly Report · 06/17 11:17
Weekly Report: what happened at VERU last week (0603-0607)?
Weekly Report · 06/10 11:20
Weekly Report: what happened at VERU last week (0527-0531)?
Weekly Report · 06/03 11:23
Russell 3000: Veru, Life MD among consumer staple additions; Benson Hill, PetMed Express among deletions
Consumer Russell 3000: Veru, Life MD among consumer staple additions; Benson Hill, PetMed Express among deletions. 225 securities will be added and 144 will be deleted as part of annual reconstitution. Russell 3000 index will have a new look on June 28.
Seeking Alpha · 05/30 21:29
Why Bank of Montreal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Bank of Montreal fell sharply after the company reported worse-than-expected second-quarter financial results. ReShape Lifesciences Inc. Shares jumped a day after receiving a patent for its obesity treatment. Other stocks moving in the mid-day session included Abercrombie & Fitch and DICK’S Sporting Goods.
Benzinga · 05/29 17:28
Comstock And 2 Other Stocks Under $2 Insiders Are Buying
When insiders purchase or sell shares, it indicates their confidence or concern about the company's prospects. The Dow Jones index closed lower by over 200 points on Tuesday. Recent notable insider transactions for penny stocks include Comstock Inc. And Veru Inc. Tecogen Inc. Has also seen a number of insider transactions.
Benzinga · 05/29 12:34
Weekly Report: what happened at VERU last week (0520-0524)?
Weekly Report · 05/27 11:27
Weekly Report: what happened at VERU last week (0513-0517)?
Weekly Report · 05/20 11:20
More
Webull provides a variety of real-time VERU stock news. You can receive the latest news about Veru through multiple platforms. This information may help you make smarter investment decisions.
About VERU
Veru Inc. is a biopharmaceutical company. The Company is focused on developing medicines for the for the treatment of hospitalized COVID-19 patients at high risk for acute respiratory distress syndrome (ARDS) and other viral-related ARDS and for the management of breast and prostate cancers. The Company offers two FDA approved products within its sexual health program, including ENTADFI (tadalafil 5mg and finasteride 5mg capsule), for the treatment of benign prostatic hyperplasia and FC2 Female Condom (internal condom) (FC2), for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. Its breast cancer drug pipeline has four clinical development programs for two drugs, such as enobosarm, an oral selective androgen receptor targeting agonist, and sabizabulin, an oral cytoskeleton disruptor. Its prostate cancer drug pipeline includes sabizabulin, VERU-100 and zuclomiphene citrate.